AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
13.95
14.37
Intervallo Annuale
4.71
18.61
Variazione giornaliera
+0.91%
Variazione Mensile
-8.19%
Variazione di 6 mesi
-2.18%
Variazione Annuale
+188.73%
Chiusura Precedente
14.2 2
Open
14.0 1
Minimo
13.9 5
High
14.3 7
Volume
666
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 2022202320242025 TTM

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notizie